Equities analysts expect Zoetis Inc. (NYSE:ZTS) to report $1.33 billion in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Zoetis’ earnings, with estimates ranging from $1.31 billion to $1.33 billion. Zoetis posted sales of $1.24 billion during the same quarter last year, which suggests a positive year over year growth rate of 7.3%. The firm is scheduled to report its next quarterly earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that Zoetis will report full-year sales of $1.33 billion for the current fiscal year, with estimates ranging from $5.17 billion to $5.25 billion. For the next financial year, analysts expect that the business will post sales of $5.54 billion per share, with estimates ranging from $5.46 billion to $5.57 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Zoetis.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, hitting the consensus estimate of $0.53. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter in the prior year, the firm earned $0.49 EPS. The company’s revenue for the quarter was up 5.0% on a year-over-year basis.

A number of analysts recently commented on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $75.00 price objective on shares of Zoetis in a report on Wednesday, September 6th. Stifel Nicolaus reissued a “buy” rating and set a $65.00 price objective on shares of Zoetis in a report on Friday, September 1st. Piper Jaffray Companies set a $73.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research report on Friday, August 25th. Cowen and Company set a $70.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research report on Thursday, August 24th. Finally, Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $62.00 target price on shares of Zoetis in a research report on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the company. Zoetis has an average rating of “Buy” and a consensus price target of $65.44.

Several large investors have recently bought and sold shares of ZTS. CGOV Asset Management raised its position in shares of Zoetis by 2.7% in the first quarter. CGOV Asset Management now owns 169,605 shares of the company’s stock valued at $12,059,000 after buying an additional 4,405 shares during the last quarter. Commerzbank Aktiengesellschaft FI raised its position in shares of Zoetis by 14.1% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 9,287 shares of the company’s stock valued at $496,000 after buying an additional 1,146 shares during the last quarter. Princeton Alpha Management LP acquired a new position in shares of Zoetis in the first quarter valued at approximately $256,000. Suntrust Banks Inc. raised its position in shares of Zoetis by 35.7% in the first quarter. Suntrust Banks Inc. now owns 70,704 shares of the company’s stock valued at $3,772,000 after buying an additional 18,589 shares during the last quarter. Finally, BNP Paribas Arbitrage SA raised its position in shares of Zoetis by 488.3% in the first quarter. BNP Paribas Arbitrage SA now owns 312,638 shares of the company’s stock valued at $16,685,000 after buying an additional 259,492 shares during the last quarter. 93.31% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Brokerages Anticipate Zoetis Inc. (ZTS) Will Announce Quarterly Sales of $1.33 Billion” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/11/brokerages-anticipate-zoetis-inc-zts-will-announce-quarterly-sales-of-1-33-billion.html.

Zoetis (ZTS) opened at 64.70 on Monday. The company’s 50 day moving average is $61.87 and its 200 day moving average is $58.97. The firm has a market cap of $31.65 billion, a P/E ratio of 36.57 and a beta of 1.02. Zoetis has a 52-week low of $46.86 and a 52-week high of $65.12.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.